The Oklahoma Medical Research Foundation's ten-year COBRE, "Science in a Culture of Mentoring (RR15577) has been transformative in providing the foundation for growth in Immunology research in our state. This COBRE provided mentoring and support to launch 12 independent research careers and the infrastructure has led to 10 "non NCRR NIH institutes" program or center grants as a direct result of this funding. OMRF and Oklahoma can now legitimately claim to be a "Center" for Immunology in the United States. Now, 16 COBRE eligible investigators present projects to be supported by mentoring and critical Core support. We have found that Mentoring and Core support is fundamental to our success. The Human Monoclonal Antibody (hmAb) Core grows out of COBRE supported scientific observations {Nature 2008), which allow rapid production of hmAbs after vaccination. With over 300 hmAbs already produced and many projects waiting, this Core is poised to provide unique research tools that should allow our COBRE Investigators to make major advances. The Serum Analyte and Biomarker Core expands on OMRF's strengths in human autoantibody detection, cytokine/chemokine measurements, epitope mapping and serum analyte development. It will provide access to the centralized generation of quality controlled data to assist projects in autoimmunity, gene-environment interactions, and human immune responses. The Immunophenotyping Core applies new whole blood multiparameter testing of detailed subsets of B cells, T cells, and other cell types. This Core provides centralized SOPs, tested reagents and experimental designs for complex human disease questions in many immunology-based projects. Finally, the Clinical Core provides patient/control identification, recruitment, phenotype characterization and human subjects training to COBRE investigators, with all 17 proposed pilot projects requesting use of this Core. The Pilot Project Core will identify, support and mentor COBRE eligible junior scientists through one-year pilot projects. Extremely productive in prior years, 17 applications were received for this cycle. We view these pilot funds as fundamental to our plans for the future of our Immunology focus in Oklahoma. The Administrative Core will provide mentoring teams and administrative support to 16 COBRE eligible junior scientists, implement and expand multidisciplinary enrichment programs, support collaborations between Oklahoma investigators, evaluate and manage the effectiveness of pilot projects. We are confident that with these additional funds OMRF and Oklahoma can have an outstanding Center of Immunology Excellence.

Public Health Relevance

This OMRF COBRE has led to an explosive expansion in Immunology based, clinically relevant research in Oklahoma. Through outside recruits and development of local junior scientists, this funding mechanism has resulted In exciting new discoveries in vaccine immunology, autoimmunity, Alzheimers'research and other complex human diseases. Transition of this productive COBRE to a Cores Center will help launch additional new investigative careers and facilitate additional Program support, from a variety of other national agencies.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Center Core Grants (P30)
Project #
5P30GM103510-05
Application #
8722573
Study Section
Special Emphasis Panel (ZRR1-RI-2 (01))
Program Officer
Douthard, Regine
Project Start
2010-09-01
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
5
Fiscal Year
2014
Total Cost
$1,223,569
Indirect Cost
$495,254
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Ratliff, Michelle L; Ward, Julie M; Merrill, Joan T et al. (2015) Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells. J Immunol 194:940-9
Freedman, Barry I; Langefeld, Carl D; Andringa, Kelly K et al. (2014) End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 66:390-6
Ward, Julie M; Rose, Kira; Montgomery, Courtney et al. (2014) Disease activity in systemic lupus erythematosus correlates with expression of the transcription factor AT-rich-interactive domain 3A. Arthritis Rheumatol 66:3404-12
Dozmorov, Mikhail G; Wren, Jonathan D; Alarcon-Riquelme, Marta E (2014) Epigenomic elements enriched in the promoters of autoimmunity susceptibility genes. Epigenetics 9:276-85
Garman, Lori; Smith, Kenneth; Farris, A Darise et al. (2014) Protective antigen-specific memory B cells persist years after anthrax vaccination and correlate with humoral immunity. Toxins (Basel) 6:2424-31
Garman, Lori; Vineyard, Amanda J; Crowe, Sherry R et al. (2014) Humoral responses to independent vaccinations are correlated in healthy boosted adults. Vaccine 32:5624-31
Ritterhouse, Lauren L; Lu, Rufei; Shah, Hemangi B et al. (2014) Vitamin d deficiency in a multiethnic healthy control cohort and altered immune response in vitamin D deficient European-American healthy controls. PLoS One 9:e94500
Young, K A; Terrell, D R; Guthridge, J M et al. (2014) Smoking is not associated with autoantibody production in systemic lupus erythematosus patients, unaffected first-degree relatives, nor healthy controls. Lupus 23:360-9
Guthridge, Joel M; Lu, Rufei; Sun, Harry et al. (2014) Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. Am J Hum Genet 94:586-98
Munroe, Melissa E; Vista, Evan S; Guthridge, Joel M et al. (2014) Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol 66:1888-99

Showing the most recent 10 out of 34 publications